Skip to main content
. 2007 Nov 26;52(2):491–496. doi: 10.1128/AAC.00909-07

FIG. 2.

FIG. 2.

Mutations present at the baseline or rebound isolates from 54 patients in which resistance to DRV was selected. Gray bars, mutations at the given amino acid positions are present in the baseline samples; black bars, mutations emerging during DRV-RTV therapy; DRV, DRV resistance mutations.